外体细胞通过miR-34a-5p/NOTCH1调节乳腺癌中的多克索鲁比抗性

相关实验视频

Updated: Jun 25, 2025

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

Nan-Nan Chen¹, Ke-Fan Zhou², Zhuang Miao¹

¹Department of Pharmacology, The Key Laboratory of Neural and Vascular Biology, Ministry of Education, The Key Laboratory of New Drug Pharmacology and Toxicology, Hebei Medical University, Shijiazhuang, 050017, Hebei, China.

Molecular and cellular probes

|May 29, 2024

概括

外体细胞通过调节miR-34a-5p和NOTCH1.1来影响乳腺癌中的阿德里亚米辛 (ADR) 耐药性. 这一发现为改善乳腺癌患者化疗疗效率提供了新的策略.

科学领域:

在瘤学瘤学.
细胞生物学细胞生物学
分子医学是分子医学.

背景情况:

乳腺癌 (BRCA) 是女性癌症死亡的主要原因.
阿德里亚米辛 (ADR/doxorubicin) 是一种关键的化疗药物,但耐药性限制了它的有效性.
外体正在成为癌症进展和耐药性的关键调解者.

研究的目的:

为了研究外体在乳腺癌细胞中的阿德里亚米辛 (ADR) 耐药性中的作用.
阐明外体细胞通过哪些分子机制来调解ADR耐药性.
确定潜在的治疗点来克服BRCA中的ADR耐药性.

主要方法:

从MCF-7和MCF-7/ADR细胞使用微分离心法提取外体.
通过激光共聚焦显微镜,MTT测定和qRT-PCR对外体对药物耐药性的影响的评估.
miRNA转染和下游基因表达和药物耐药性变化的评估.

主要成果:

来自ADR耐药细胞的外体细胞 (ADR/exo) 在敏感的MCF-7细胞中增加了ADR耐药性.
在耐药细胞及其外体细胞中观察到miR-34a-5p表达的显著差异.
miR-34a-5p与NOTCH1表达有负相关性,这表明一种调节途径.

结论:

外体细胞通过miR-34a-5p/NOTCH1通路在乳腺癌细胞中调解ADR耐药性.
外基因组可以在细胞之间运输功能性miRNA,从而影响耐药性.
向外体miR-34a-5p/NOTCH1轴可能会提高BRCA的化疗疗效率.

关键词:

乳腺癌是什么? 乳腺癌是什么?化学抗药性化学抗药性是一种抗药性.德克索鲁比辛是一种多克索鲁比辛.异构体是什么? 异构体是什么? 外构体是什么?这是一个小RNARNA.

更多相关视频

Exosomal miRNA Analysis in Non-small Cell Lung Cancer NSCLC Patients' Plasma Through qPCR: A Feasible Liquid Biopsy Tool

Exosomal miRNA Analysis in Non-small Cell Lung Cancer NSCLC Patients' Plasma Through qPCR: A Feasible Liquid Biopsy Tool

Published on: May 27, 2016

Preparation of Exosomes for siRNA Delivery to Cancer Cells

Preparation of Exosomes for siRNA Delivery to Cancer Cells

Published on: December 5, 2018

相关概念视频

Overview of Exosomes

Overview of Exosomes

Exosomes are stable, lipid bilayer-enclosed vesicles capable of crossing biological barriers. They can carry a wide range of molecules required for intercellular communication. Once exosomes are released from the cell where they originated, they enter a recipient cell through various pathways such as fusion, receptor-mediated endocytosis, macropinocytosis, and phagocytosis.
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...

Receptor Downregulation in MVBs

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...

MicroRNAs

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...